Current Headlines

  1. Former BD CEO Leads $3.5M Investment in Velano Vascular's Needle-Free Blood Draw Device
    2/8/2016

    Velano Vascular, a medical technology company transforming and enhancing the care experience for hospitalized patients and their practitioners, announced today that the company has raised an additional $3.5 million in funding. Velano will use the proceeds from this financing, an extension of a $5 million Series A financing completed inJanuary 2015, to support the development and commercialization of the company's inpatient blood-draw technology in adult and pediatric populations.

  2. St. Jude Launches Mobile OCT Imaging, Angiography System In Europe And Japan
    2/8/2016

    St. Jude Medical, Inc. has announced the launch of the company’s OPTIS Mobile System in Japan and Europe. The diagnostic system is designed to couple state-of-the-art optical coherence tomography and angiography co-registration with fractional flow reserve technology into one portable system for hospitals with multiple catheterization labs.

  3. Boston Scientific Ramping Up Watchman, S-ICD Programs
    2/8/2016

    Boston Scientific is ramping up its Watchman anti-stroke device program in anticipation of a National Coverage Determination from the Centers for Medicare & Medicaid Services (CMS). The device maker also is optimistic that it will reverse a decline in cardiac rhythm management (CRM) sales by the end of 2016, based partially on growing adoption of its Subcutaneous Implantable Cardioverter Defibrillator (S-ICD) system.

  4. Acquisitions, R&D Focus Drive S&N In 2016
    2/8/2016

    Smith & Nephew’s (S&N) multi-year strategy to reorganize and diversify is starting to show results, said CEO Olivier Bohoun. Recent acquisitions in sports medicine and robotic surgery, as well as expanded focus in emerging markets and R&D have accelerated growth, a trend Bohoun expects to continue through 2016.

  5. NIH Backs Artificial Pancreas Trial By Partners Cellnovo, TypeZero
    2/5/2016

    Cellnovo Group is partnering with technology company TypeZero to utilise Cellnovo’s e-connected insulin patch pump alongside its inControl AP software in an artificial pancreas program. This joint system will be in consideration for use in the International Diabetes Closed Loop Trial, which is funded by the National Institute of Health.

  6. BD CEO: Medtronic Collaboration On Novel Infusion Set “On Track”
    2/5/2016

    Becton, Dickinson and Company (BD) CEO Vincent A. Forlenza told investors recently that an ongoing partnership with Medtronic on a new insulin infusion set is on track, and unveiled the company's pipeline of new products in 2016, including a couple of new cell analyzers with faster simultaneous measurement capabilities. He also confirmed that savings from the medical device tax suspension will be re-invested into R&D.

  7. FDA Offers Extension For Some UDI Implementation Deadlines
    2/5/2016

    The U.S. Food and Drug Administration (FDA) is giving original equipment manufacturers (OEMs) some additional time to remove legacy FDA labels from medical devices, citing concerns from payers and pharmacies that removing the labels prematurely would interfere with patient access. Certain medical devices manufactured before September 2018 will have until September 2021 to remove the legacy labels.

  8. Nikon Invests $10M In Hand-Held X-Ray Analyzer Maker Tribogenics
    2/4/2016

    Tribogenics, the inventor of triboluminescence based X-ray technology for industrial, security and scientific applications, announced today that Nikon Americas Inc. has made a strategic investment in Tribogenics. Nikon Group’s investment will help speed the commercialization of Tribogenics’ Watson, hand-held XRF analyzer products.

  9. Abbott's Needle-Free Glucose Monitor Receives CE Mark For Children Aged 4 To 17 Years
    2/4/2016

    Abbott has obtained CE Mark (Conformité Européenne) for the FreeStyle Libre flash glucose monitoring system indicated for children and teens with diabetes aged 4-17 years old. This means that children and young people with diabetes living in Europe are able to experience the liberation from the pain and hassle of routine finger pricks.

  10. Edwards CEO Touts Increased Adoption of TAVR Program
    2/4/2016

    Edwards Lifesciences reported a strong fourth quarter performance built on increased adoption of transcatheter-based heart valve therapies, and company CEO Michael A. Mussallem believes momentum will likely continue this year as the company receives more indications for its Sapien 3 implant.